A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Public ClinicalTrials.gov record NCT03478696. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase IV, 12-week, Randomised, Double-blind, Triple Dummy Study to Compare Single Inhaler Triple Therapy, Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) With Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) Based on Lung Function and Symptoms in Participants With Chronic Obstructive Pulmonary Disease
Study identification
- NCT ID
- NCT03478696
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Lead sponsor
- GlaxoSmithKline
- Industry
- Enrollment
- 732 participants
Conditions and interventions
Conditions
Interventions
- ELLIPTA Device
- FF/UMEC/VI Drug
- HandiHaler Device
- MDI Device
- Placebo to match FF/UMEC/VI Drug
- Placebo to match budesonide/formoterol Drug
- albuterol/salbutamol Drug
- budesonide/formoterol Drug
- placebo to match tiotropium Drug
- tiotropium Drug
Device · Drug
Eligibility (public fields only)
- Age range
- 40 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 24, 2018
- Primary completion
- Mar 17, 2019
- Completion
- Mar 17, 2019
- Last update posted
- Oct 27, 2020
2018 – 2019
United States locations
- U.S. sites
- 42
- U.S. states
- 16
- U.S. cities
- 38
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Mobile | Alabama | 36608 | — |
| GSK Investigational Site | Bakersfield | California | 93301 | — |
| GSK Investigational Site | Sacramento | California | 95823 | — |
| GSK Investigational Site | San Diego | California | 92120 | — |
| GSK Investigational Site | Westminster | California | 92683 | — |
| GSK Investigational Site | Celebration | Florida | 34747 | — |
| GSK Investigational Site | Clearwater | Florida | 33765 | — |
| GSK Investigational Site | Hialeah | Florida | 33016 | — |
| GSK Investigational Site | Kendall | Florida | 33175 | — |
| GSK Investigational Site | Leesburg | Florida | 34748 | — |
| GSK Investigational Site | Longwood | Florida | 32750 | — |
| GSK Investigational Site | Miami | Florida | 33125 | — |
| GSK Investigational Site | Miami | Florida | 33126 | — |
| GSK Investigational Site | Miami | Florida | 33133 | — |
| GSK Investigational Site | Miami | Florida | 33155 | — |
| GSK Investigational Site | Miami | Florida | 33165 | — |
| GSK Investigational Site | Sebring | Florida | 33870 | — |
| GSK Investigational Site | Winter Park | Florida | 32789 | — |
| GSK Investigational Site | Dacula | Georgia | 30019 | — |
| GSK Investigational Site | Duluth | Georgia | 30096 | — |
| GSK Investigational Site | Rincon | Georgia | 31326 | — |
| GSK Investigational Site | Evanston | Illinois | 60201 | — |
| GSK Investigational Site | Evansville | Indiana | 47714 | — |
| GSK Investigational Site | Farmington Hills | Michigan | 48336 | — |
| GSK Investigational Site | Rochester | Michigan | 48307 | — |
| GSK Investigational Site | St Louis | Missouri | 63141 | — |
| GSK Investigational Site | Charlotte | North Carolina | 28207 | — |
| GSK Investigational Site | Mooresville | North Carolina | 28117 | — |
| GSK Investigational Site | Cincinnati | Ohio | 45231 | — |
| GSK Investigational Site | Grove City | Ohio | 43123 | — |
| GSK Investigational Site | Jefferson Hills | Pennsylvania | 15025 | — |
| GSK Investigational Site | Clinton | South Carolina | 29325 | — |
| GSK Investigational Site | Greenville | South Carolina | 29615 | — |
| GSK Investigational Site | Mt. Pleasant | South Carolina | 29464 | — |
| GSK Investigational Site | Spartanburg | South Carolina | 29303 | — |
| GSK Investigational Site | Union | South Carolina | 29379 | — |
| GSK Investigational Site | Tullahoma | Tennessee | 37388 | — |
| GSK Investigational Site | Boerne | Texas | 78006 | — |
| GSK Investigational Site | McKinney | Texas | 75069 | — |
| GSK Investigational Site | San Antonio | Texas | 78229 | — |
| GSK Investigational Site | Richmond | Virginia | 23225 | — |
| GSK Investigational Site | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 15 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03478696, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 27, 2020 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03478696 live on ClinicalTrials.gov.